The University of Tennessee Graduate School of Medicine, Knoxville

The Department of Medicine

William B. Smith, MD

Division of Cardiology


Medical School
Universidad Autonoma de Guadalajara

Internal Medicine, University of Tennessee Medical Center

Cardiology, Tulane University Medical Center and Affiliated Hospitals, New Orleans, LA
Nephrology, Vanderbilt University, Nashville, TN


American Board of Internal Medicine
American Board of Internal Medicine - Cardiovascular Disease
American Board of Internal Medicine - Nephrology

Current Publications

Smith W, Wan H, Much D, Robinson AG, Martin P.
Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: A phase 4, double-blind, placebo-controlled, randomized, tilt-table study. Clinical Autonomic Research. 2016 Jul 2. [Epub ahead of print]

Frenck RW Jr, Fiquet A, Gurtman A, van Cleeff M, Davis M, Rubino J, Smith W, Sundaraiyer V, Sidhu M, Emini EA, Gruber WC, Scott DA, Schmoele-Thoma B.
Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine. 2016 Jun 24;34(30):3454-62. Epub 2016 May 5.

Rodriguez-Torres M, Glass S, Hill J, Freilich B, Hassman D, Di Bisceglie AM, Taylor JG, Kirby BJ, Dvory-Sobol H, Yang JC, An D, Stamm LM, Brainard DM, Kim S, Krefetz D, Smith W, Marbury T, Lawitz E.
GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. Journal of Viral Hepatitis. 2016 Mar 9. [Epub ahead of print]

Adkison KK, Gan J, Elko-Simms L, Gardner S, Dumont E, Jones LS, Saunders J, Marbury T, Smith W, Berg J, Galloway C, Stump PJ.
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment. Journal of Clinical Pharmacology . 2015 Sep;55(9):1042-50. Epub 2015 May 25.

Zhang M, Xu C, Ma L, Shamiyeh E, Yin J, von Moltke LL, Smith WB.
Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers. Clinical Pharmacology in Drug Development. 2015 Jul;4(4):315-321.

Yang BB, Gillespie B, Smith B, Smith W, Lissmats A, Rudebeck M, Kullenberg T, Olsson B.
Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin. Journal of Clinical Pharmacology . 2015 Apr 15. [Epub ahead of print]

Devineni D, Curtin CR, Marbury TC, Smith W, Vaccaro N, Wexler D, Vandebosch A, Rusch S, Stieltjes H, Wajs E.
Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clinical Therapeutics . 2015 Mar 1;37(3):610-628.e4.

Heald AE, Iversen PL, Saoud JB, Sazani P, Charleston JS, Axtelle T, Wong M, Smith WB, Vutikullird A, Kaye E.
Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: Results of two single ascending dose studies. Antimicrobial Agents and Chemotherapy. 2014 Nov;58(11):6639-47.

Zhang M, Xu CR, Shamiyeh E, Yin JY, Liu F, Von Moltke LL, Smith WB.
A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. Journal of Clinical Pharmacology. 2014 Apr;54(4):415-421

Lauring B, Li X, Liu Y, Corr C, Lazarus N, Cote J, Larson P, Levonas AOJ, Lai E, Wagner JA, Lasseter KC, Preston RA, Smith WB.
Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. Journal of Clinical Pharmacology. 2014 Apr [Epub ahead of print]


Support The University of Tennessee Graduate School of Medicine

The University of Tennessee Graduate School of Medicine
1924 Alcoa Highway
Knoxville, Tennessee 37920 | 865-305-9290

Copyright © 2017